Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
AssigneeFive Prime Therapeutics, Inc.
InventorsSusannah D. BARBEE, Thomas BRENNAN, Barbara SENNINO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
Claims61
A method of treating a PD-L1 negative tumor in a subject, the method comprising administering to the subject a composition comprising CD80 extracellular domain (ECD) fusion molecules.
A method of selecting a subject with a tumor for treatment with a composition comprising CD80 ECD fusion molecules, the method comprising determining whether a tumor sample obtained from the subject is PD-L1 negative and selecting the subject for treatment with the composition if the tumor sample is determined to be PD-L1 negative.
A composition comprising CD80 ECD fusion molecules for use in the treatment of a PD-L1 negative cancer tumor in a subject.
A composition comprising CD80 ECD fusion molecules for use in the treatment of a tumor in a subject, wherein the tumor has been determined to be PD-L1 negative.
An in vitro method for identifying a subject with a tumor that is responsive to treatment with a composition comprising CD80 ECD fusion molecules, the method comprising determining whether a tumor sample obtained from the subject is PD-L1 negative, wherein the subject is identified as being responsive to treatment with a CD80 ECD fusion molecule if the tumor sample is determined to be PD-L1 negative.
An in vitro use of at least one agent capable of determining that a tumor sample is PD-L1 negative, for identifying a subject with a tumor that is responsive to treatment with a composition comprising CD80 ECD fusion molecules.
A method of treating a PD-L1 negative tumor in a human patient, the method comprising administering to the patient a composition comprising about 0.07 mg to about 70 mg CD80 extracellular domain (ECD) fusion molecules comprising the amino acid sequence of SEQ ID NO:5.
Dependencies are inferred from the claim text.